All In Biotech

BLA 103772 · Centocor INC

Remicade

Infliximab · Tumor Necrosis Factor Blocker

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Feb 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1998

Aug 24, 1998

Approved uses

17

Original approval plus efficacy supplements

Registered trials

379

125 Phase 3, 45 recruiting

FAERS reports

217,587

192,742 serious, 14,068 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. ( 5.1 ) Discontinue Infliximab if a patient develops a serious infection. Perform test for latent TB; if positive, start treatment for TB prior to starting Infliximab. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. ( 5.1 ) Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including Infliximab. ( 5.2 ) Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have...

What it is approved for

From the label in effect Feb 11, 2026.

Infliximab is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis : reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis : reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis : reducing signs and symptoms in adult patients with active disease. ( 1.6 ) Psoriatic Arthritis : reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. ( 1.7 ) Plaque Psoriasis :...

Mechanism: Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms of TNFα and inhibits binding of TNFα with its receptors. Infliximab does not neutralize TNFβ (lymphotoxin-α), a related cytokine that utilizes the same receptors as TNFα. Biological activities attributed to TNFα include: induction of pro-inflammatory cytokines such as interleukins (IL) 1 and 6, enhancement of leukocyte migration by increasing endothelial layer permeability and expression of adhesion molecules by endothelial cells and leukocytes, activation of neutrophil...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • REMICADE · INFLIXIMAB 100MG · VIAL, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Infliximab" as an intervention, any sponsor and status, largest first.

All 379 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective39,857
  • off label use39,149
  • condition aggravated20,002
  • infusion related reaction19,191
  • pain18,649
  • rheumatoid arthritis18,613
  • arthralgia17,843
  • fatigue16,776
  • rash13,431
  • product use issue13,143
  • intentional product use issue13,103
  • drug intolerance12,543

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,914
20053,404
20063,607
20074,090
20084,335
20095,091
20106,225
20118,099
201212,244
20139,120
20145,999
201512,316
20169,599
201710,037
201811,094
201913,337
202017,812
202113,063
202218,658
202314,184
202412,379
202512,090
20266,872

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Remicade (Infliximab)

2024 spending

$119M

Beneficiaries

3,243

17,640 claims

Per beneficiary

$36,632

$1,068.59 per unit

View as table
YearSpending
2020$99,404,194
2021$102,739,191
2022$102,555,823
2023$111,268,849
2024$118,798,517

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,999 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.